mRNA Therapeutics CDMO Global Market Report 2026

An mRNA therapeutics CDMO, or messenger ribonucleic acid therapeutics contract development and manufacturing organization, is a specialized third-party entity that offers comprehensive support for the research, development, and large-scale production of mRNA-based therapeutic agents under contractual agreements with pharmaceutical or biotechnology companies. These organizations play a key role in accelerating time-to-market, maintaining regulatory compliance, and providing flexible manufacturing capacity for mRNA therapeutic pipelines.

The main types of services offered by mRNA therapeutics CDMOs include development services, manufacturing services, and laboratory services. Development services encompass end-to-end support for the design, optimization, and scale-up of mRNA therapeutics, including synthesis, formulation, analytical development, and process development tailored to client-specific products. These therapeutics are applied across indications such as infectious diseases, metabolic and genetic disorders, and cardiovascular and cerebrovascular conditions, and are used in applications including viral vaccines, protein replacement therapies, and cancer immunotherapies. The end users include pharmaceutical companies, biotechnology firms, academic institutions, and research organizations.

Tariffs have impacted the mRNA therapeutics CDMO market by increasing costs for imported raw materials, specialized reagents, and advanced laboratory equipment required for mRNA synthesis and LNP formulation. Segments such as plasmid DNA manufacturing, fill-finish services, and viral vaccine production are most affected, particularly in regions like Asia-Pacific including China and India. While tariffs create short-term cost pressures and supply chain challenges, they also encourage domestic production, local sourcing of materials, and innovation in manufacturing efficiency.

The mrna therapeutics cdmo market research report is one of a series of new reports from The Business Research Company that provides mrna therapeutics cdmo market statistics, including mrna therapeutics cdmo industry global market size, regional shares, competitors with a mrna therapeutics cdmo market share, detailed mrna therapeutics cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the mrna therapeutics cdmo industry. This mrna therapeutics cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mrna therapeutics cdmo market size has grown rapidly in recent years. It will grow from $4.74 billion in 2025 to $5.31 billion in 2026 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to limited availability of specialized mrna cdmo services, reliance on in-house pharmaceutical manufacturing, growing infectious disease outbreaks, adoption of early-stage analytical testing, expansion of academic and research collaborations.

The mrna therapeutics cdmo market size is expected to see rapid growth in the next few years. It will grow to $8.26 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to rising investment in mrna therapeutics pipelines, technological advancements in plasmid dna and mrna synthesis, growth of cancer immunotherapy and protein replacement therapies, increasing demand for fill-finish services, expansion of partnerships between biotechs and cdmos. Major trends in the forecast period include rising demand for outsourced mrna development and manufacturing, increasing focus on lipid nanoparticle (lnp) formulation technologies, expansion of viral vaccine and cancer immunotherapy pipelines, enhanced regulatory compliance and quality assurance measures, growing adoption of analytical and bioanalytical laboratory services.

The growing burden of chronic and infectious diseases is expected to drive growth in the mRNA therapeutics CDMO market in the coming years. Chronic and infectious diseases include long-term health conditions such as diabetes, cardiovascular disorders, and asthma, as well as illnesses caused by pathogenic microorganisms like viruses, bacteria, and parasites, which can spread directly or indirectly among individuals. The prevalence of these diseases is rising due to aging populations, which are more vulnerable to both long-term illnesses and infections. mRNA therapeutics CDMOs help address these conditions by providing end-to-end development and manufacturing services that accelerate the delivery of targeted, personalized mRNA therapies to patients. For example, in October 2024, the World Health Organization, a Switzerland-based international public health organization, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from around 7.5 million in 2022, highlighting the escalating global burden of infectious diseases. This indicates that the increasing prevalence of chronic and infectious diseases is fueling growth in the mRNA therapeutics CDMO market.

Key companies in the mRNA therapeutics CDMO market are focusing on innovative solutions, such as in situ nanomedicine vaccines, to improve the effectiveness and precision of mRNA-based vaccines through targeted immune stimulation. An in situ nanomedicine vaccine is a next-generation mRNA therapeutic designed to produce nanomedicines within the patient's body, enabling targeted delivery and customized immune activation through engineered transgene expression. For instance, in January 2025, Esphera SynBio Inc., a Canada-based biotechnology company, launched a project supported by the CQDM Quantum Leap program. The initiative seeks to enhance first-generation lipid nanoparticle/mRNA (LNP/mRNA) vaccines by incorporating proprietary transgene designs that induce in vivo production of immunostimulatory nanomedicines. This technology allows precise antigen delivery and tailored immune responses, representing a potential breakthrough in vaccine development.

In September 2024, Agilent Technologies Inc., a U.S.-based medical equipment company, acquired BIOVECTRA for $0.925 billion. The acquisition aims to expand Agilent's CDMO capabilities into high-growth modalities, including mRNA therapeutics, by leveraging BIOVECTRA's expertise in biologics and advanced pharmaceutical manufacturing. BIOVECTRA is a Canada-based contract development and manufacturing organization specializing in mRNA therapeutics and other modalities.

Major companies operating in the mrna therapeutics cdmo market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG.

North America was the largest region in the mRNA therapeutics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mrna therapeutics cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mRNA therapeutics CDMO market consists of revenues earned by entities by providing services such as supply chain management, cold chain logistics, quality assurance auditing, clinical trial material preparation, batch release testing, serialization, and packaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The mRNA therapeutics CDMO market also includes sales of products such as lipid excipients, nucleotide reagents, capping analogs, custom RNA oligonucleotides, and modified nucleosides. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

mRNA Therapeutics CDMO Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses mrna therapeutics cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mrna therapeutics cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mrna therapeutics cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type Of Service: Development Services; Manufacturing Services; Laboratory Services
• 2) By Indication: Infectious Diseases; Metabolic And Genetic Diseases; Cardiovascular And Cerebrovascular Diseases
• 3) By Application: Viral Vaccines; Protein Replacement Therapies; Cancer Immunotherapies
• 4) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic Institutions; Research Organizations
• Subsegments:
• 1) By Development Services: Process Development; Analytical Method Development; Formulation Development; Regulatory Support
• 2) By Manufacturing Services: Plasmid DNA Manufacturing; mRNA Synthesis; Lipid Nanoparticle (LNP) Formulation; Fill-Finish Services
• 3) By Laboratory Services: Quality Control Testing; Stability Testing; Bioanalytical Testing; Preclinical Testing
• Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; FUJIFILM Holdings Corporation; Evonik Industries AG; AGC Biologics GmbH; Eurofins Scientific SA; Samsung Biologics Co. Ltd.; Wuxi Biologics; Recipharm AB; EMERGENT BioSolutions Inc.; Genscript Biotech; Ginkgo Bioworks Holdings Inc.; Corden Pharma Corp.; TriLink BioTechnologies LLC; Biocina Pty Ltd.; Aldevron LLC; Synbio Technologies LLC; etherna manufacturing; Bio-Synthesis Inc.; Biomay AG.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.